3 Stocks on Sale: Deckers, Walgreens, and PPG
Investors have three bargain stocks to consider. After falling by 20.5% on Jan. 31, 2025, Deckers Outdoor (DECK) shares are on sale.The company posted third-quarter revenue of $1.8 billion, growing by 17% Y/Y. CEO Stefano Caroti said that UGG and HOKA brands drove gross margins to 60.3%. EPS grew by 19% to $3.00.Deckers raised its 2025 revenue outlook to around $4.9 billion (+15% Y/Y).Walgreens Boots (WBA) lost 10.3% on Jan. 31. The firm, as expected, suspended its cash dividend. The stock previously paid a dividend that yielded 9%, an unsustainable rate.WBA stock pared losses on the day as speculators bet on Sycamore Partners buying out the firm. However, the chances of a takeover are low. Shareholders may prefer CEO Tim Wentworth to restructure the drugstore by cutting costs, closing stores, and improving profitability.PPG Industries (PPG) ended its rebound when shares lost 6%. The paints, coatings, and specialty materials provider earned $1.61 in non-GAAP EPS. Revenue fell by 4.6% Y/Y to $3.73 billion. PPG stock sold off because the $7.75-$8.05 EPS forecast for 2025 is below consensus estimates.PPG has restructuring efforts that would save $175 million in costs this year. It is also consolidating its European manufacturing business.Investors wary of PPG’s prospects may consider DuPont (DD) or International Flavors & Fragrances (IFF) instead.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


